Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing eye injections: could 3, 7, or 14 days before surgery matter?

NCT ID NCT06300918

Disease control Sponsor: Jie Li Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether giving anti-VEGF injections 3, 7, or 14 days before surgery makes a difference for people with proliferative diabetic retinopathy, a complication of diabetes that causes abnormal blood vessels in the eye. Participants are randomly assigned to one of three timing groups. Using a new technique that allows fluorescein angiography during surgery, the study will compare how well each timing suppresses these abnormal vessels, aiming to identify the most effective approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anti-VEGF drugs (injected into the eye before surgery)
What this could lead to
If successful, this could identify the optimal timing for anti-VEGF injections before surgery, potentially improving outcomes for people with proliferative diabetic retinopathy.
What could go wrong
This is a small, early-stage trial, and the results may not apply to all patients. The best timing could vary based on individual factors, and the study may not find a clear difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PDR is diagnosed in people 18 years of age or older with type 1 or type 2 diabetes， * Hemoglobin A1c (HbA1c) ≤10% * Persistent vitreous hemorrhage for more than one month or recurrent vitreous hemorrhage (within six months) * Did not undergo retintis photocoagulation (PRP) * Vitreous hemorrhage disease course within six months Exclusion Criteria: * Patients who have had previous vitreoretinal surgery * Intravitreal drug injection within 3 months * Eye diseases other than PDR that may hinder vision improvement, such as optic atrophy or macular hole * Thromboembolic events (including cerebrovascular or myocardial infarction) or clotting system disorders or receiving anticoagulation or antiplatelet therapy * B-ultrasound or indirect fundus microscopy showing retina detachment (pull or hole origin) * Vitrectomy, FFA contraindicated patients, patients with severe abnormality of cardiopulmonary, liver and kidney function

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Proliferative diabetic retinopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

choroidal neovascularization proliferative diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

The condition of fundus neovascularization

Contacts and locations

Locations

  • Sichuan Academy of Medical Science Sichuan Provincial Hosptial

    Chengdu, Sichuan, 610014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.